ClinicalTrials.gg
CompletedNCT00308477Updated Feb 13, 2012

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion

A Phase 1/2 interventional study of dexamethasone in Macular Degeneration, Macular Edema and Branch Retinal Vein Occlusion, sponsored by Sanwa Kagaku Kenkyusho Co., Ltd.. Completed at 12 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2012-02-13.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Allocation
Non-randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 56 studies testing dexamethasone in Macular Edema — 3 open to participants now, 3 under way, 1 of them phase 3. Dexamethasone · Macular Edema.

Phase 1/2
3 of 56
1 open now
Registered
5th of 56
by date

Among the 56 studies testing dexamethasone in Macular Edema, this one is one of 3 in phase 1/2, and was the 5th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

3 of the 56 studies testing dexamethasone in Macular Edema are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing dexamethasone in Macular Edema, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone for the treatment of macular edema associated with branch retinal vein occlusion.

03

Conditions studied

  • Macular Degeneration
  • Macular Edema
  • Branch Retinal Vein Occlusion

Browse trials for

Keywords

  • eye diseases
04

In context

Macular Edema Reclassified

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Lead sponsor

Sanwa Kagaku Kenkyusho Co., Ltd. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Macular edema resulting from branch retinal vein condition
  • The criteria for visual acuity and macular thickness are met

Exclusion criteria

Exclusion Criteria:

  • History of glaucoma
  • Diabetic retinopathy
  • Known -responder
  • Use of systemic steroids
  • Use of Warfarin/Heparin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)

Interventions

07

Study locations

12 sites
  • Aichi, Japan
  • Chiba, Japan
  • Fukuoka, Japan
  • Gunma, Japan
  • Hokkaido, Japan
  • Kagawa, Japan
  • Kyoto, Japan
  • Mie, Japan
  • Miyazaki, Japan
  • Osaka, Japan
  • Shiga, Japan
  • Tokyo, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00308477
Lead sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
First posted
Mar 29, 2006
Last update
Feb 13, 2012

Study contacts

Clinical Study Group, Clinical Development Dept.
study director · Sanwa Kagaku Kenkyusho Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion